Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dexrazoxane for anthracycline extravasation.

Seppo W Langer1

  • 1Copenhagen University Hospital, Rigshospitalet, Department of Oncology, Section 5073, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. seppo.langer@rh.regionh.dk

Expert Review of Anticancer Therapy
|November 22, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to "Methodological and inferential limits before abandoning follow-up in node-negative typical lung carcinoids".

Journal of neuroendocrinology·2026
Same author

Controversies in neuroendocrine neoplasms: An European Neuroendocrine Tumor Society position statement on the role of surgery of the primary tumour in metastatic small intestinal and pancreatic neuroendocrine tumours.

Journal of neuroendocrinology·2026
Same author

Follow-up is not justified in patients with typical lung carcinoids without lymph node involvement treated with curative intent: A Danish Multi-ENETS Center of Excellence Study.

Journal of neuroendocrinology·2026
Same author

Responses to medical treatment in patients with metastatic unresectable small intestinal neuroendocrine tumors - A single center study of 378 patients.

Journal of neuroendocrinology·2026
Same author

Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas.

International journal of cancer·2026
Same author

Malignancy Detection Rates of [<sup>68</sup>Ga]Ga-SSO120 PET/CT in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Lung Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.

Expert review of anticancer therapy·2026
Same journal

Barriers to the use of brachytherapy for treatment of cervical cancer and prostate cancer in low- and middle-income countries.

Expert review of anticancer therapy·2026
Same journal

The dual role of Schlafen11 in brain tumors: Jekyll and Hyde.

Expert review of anticancer therapy·2026
Same journal

Central nervous system-related permanent consequences in long-term survivors of pediatric Langerhans cell histiocytosis: a clinical overview and monitoring strategies.

Expert review of anticancer therapy·2026
Same journal

RTsDEN: reverse task attention enabled deep learning model for lung cancer detection using computed tomography.

Expert review of anticancer therapy·2026
Same journal

The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma.

Expert review of anticancer therapy·2026
See all related articles

Anthracycline extravasation causes severe tissue damage. Dexrazoxane is the first and only proven effective antidote, preventing necrosis and reducing the need for surgery.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Accidental extravasation of anthracycline chemotherapy can cause severe tissue damage and long-term complications.
  • Effective treatments for anthracycline extravasation have been lacking.

Purpose of the Study:

  • To evaluate the efficacy of dexrazoxane as an antidote for anthracycline extravasation.

Main Methods:

  • Preclinical and clinical studies were conducted to assess dexrazoxane's effectiveness.
  • Review of existing data on dexrazoxane's impact on preventing necrosis.

Main Results:

  • Dexrazoxane demonstrated high efficacy in preventing necrosis associated with anthracycline extravasation.
  • Dexrazoxane is approved in Europe (Savene) and has orphan drug status in the USA (Totect).

Related Experiment Videos

Conclusions:

  • Dexrazoxane is the first and only clinically proven effective antidote for anthracycline extravasation injuries.
  • It significantly reduces tissue damage and the need for surgical intervention.